Protagenic Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.
On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid price of $1.00 per share for 30 consecutive trading days. The Notification Letter stated that the company had 180 calendar days, or until May 19, 2024, to regain compliance by having a closing bid price of at least $1.00 per share for ten consecutive trading days. On March 19, 2024, the company received a formal notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).
About Protagenic Therapeutics, Inc.:
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit www.protagenic.com.
About PT00114:
PT00114, a 41-amino-acid synthetic peptide, holds promise in treating various neuro-psychiatric conditions, including depression, anxiety, and PTSD. It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence23.12.2024 08:00:00 CET | Press release
Matrix streamlines document processing by cutting manual labor and operational costs, using AI agents in the enterprise. LONDON, GB / ACCESSWIRE / December 23, 2024 / Today, Beyond Work, an enterprise AI company, announced the record-setting results of Matrix, a novel memory-augmented AI framework for automating business document processing. Developed in collaboration with researchers from Penn State University, Oregon State University, and Kuehne+Nagel, one of the world's largest logistics providers, Matrix addresses the complex, time-intensive task of extracting transport references from Universal Business Language (UBL) invoices.MATRIX Results Comparing the success rates of four methods (CoT, Two-agent, Reflexion, Matrix) across GPT-4o-mini and GPT-4o, with Matrix achieving the highest performance. By harnessing an iterative, memory-centric learning strategy, Matrix achieves a 30.3% improvement over chain-of-thought prompting, outperforms a standard Large Language Model agent by 35.
Brightline Interactive Successfully Delivers A Scalable Immersive Simulation To A Global Government Service Integrator, Positioning Itself As A Leading Operating System For Processing And Visualizing Complex Information In 3D Space23.12.2024 07:00:00 CET | Press release
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, today announced that its subsidiary company Brightline Interactive, LLC ("BLI") successfully delivered a paid for advanced immersive simulation through its cutting-edge middleware platform - SpatialCore - to a large government services integrator ("GSI"). Leveraging the power of SpatialCore's spatial computing and AI platform, BLI was able to create a sophisticated spatial simulation in record time, setting what we believe has the potential to become a new industry standard. This initial simulation project was developed with the goal of allowing the GSI to gather simulation needs from others and to then add to this build, or for further deployment, in a cost effective and scalable manner. Tyler Gates, Genera
MicroVision Increases Production Capacity to Meet Anticipated Demand19.12.2024 09:20:00 CET | Press release
REDMOND, WA / ACCESSWIRE / December 19, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced that it has increased production capacity for its MOVIA L sensor to meet anticipated demand from the industrial sector. Building on the relationship with its existing automotive Tier 1 manufacturing partner, MicroVision expects output of MOVIA L sensors for 2025 to significantly increase compared to 2024. The continued acceleration of production capacity throughout 2025 will result in a reduced average cost per sensor, while maintaining a high-quality product suitable for industrial applications. "Securing this production capacity is critical to support high-volume orders from industrial customers, so we feel good closing out the year with this commitment in hand," said Sumit Sharma, Chief Executive Officer. "We are pleased with this scaling, particularly from a cost perspective, and our Tier 1 automotive supplier, ZF, i
Brightline Interactive Enters into an Agreement with the U.S. Navy for an Immersive, AI-Driven Simulator System19.12.2024 07:00:00 CET | Press release
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, today announced that its subsidiary company Brightline Interactive, LLC ("BLI") has entered into an initial six figure dollar contract with the U.S. Navy for an Immersive Simulator, to be delivered in the first half of 2025. Tyler Gates, General Manager of BLI and Chief Futurist of Glimpse, commented: "Powered by BLI's cutting-edge spatial computing platform ("SpatialCore"), we have created a game-changing technology that pushes the boundaries of what's possible via the integration of AI and Spatial Computing. The Immersive Simulator system seamlessly integrates AI into both the full motion simulation and the spatial computing environments in which they operate, offering unparalleled realism, responsiveness,
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP19.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon the positive International Preliminary Report on Patentability (IPRP) issued by the European Patent Office (EPO) in September 2024, BioNxt has initiated national-level filings in key jurisdictions, including the United States, Canada, Europe, and Japan. These patents are designed to protect the Company's proprietary sublingual formulations of anticancer drugs repurposed for the treatment of conditions such as Multiple Sclerosis (MS). "Securing robust intellectual property rights across major markets is a critical component of our strategy to bring innovative, patien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom